BIOPORTO A/S |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.25 DKK | +0.81% |
|
+2.29% | -40.19% |
Presenter SpeechAnthony Pare (Executives)We welcome questions and clarification requests at th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Companyâs portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Calendar
2024-04-30
- Annual General Meeting
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.24
DKK
Average target price
5
DKK
Spread / Average Target
+303.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.19% | 67.41M | |
| +0.80% | 12.8B | |
| -10.29% | 7.61B | |
| +3.24% | 5.41B | |
| -1.16% | 4.51B | |
| +6.06% | 4.49B | |
| +12.21% | 2.73B | |
| -14.07% | 2.02B | |
| -11.50% | 1.73B | |
| -4.18% | 1.64B |
- Stock Market
- Equities
- BIOPOR Stock
- News BioPorto A/S
- Transcript : BioPorto A/S, Q2 2023 Earnings Call, Aug 01, 2023
